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0929-6646/Copyright ª 2014, ElsevierBackground/Purpose: Pulmonary endarterectomy (PEA) is a potentially curative surgical pro-
cedure for patients with chronic thromboembolic pulmonary hypertension. The aim of this
study is to review our institutional experience with this operation.
Methods: We conducted a retrospective review of PEA performed at our institution between
January 2005 and December 2013. The measured outcomes were inhospital complications,
improvement in cardiac function and exercise capacity, and actuarial survival after PEA.
Results: Ten consecutive patients (7 women, 3 men) underwent PEA with a mean age of
59.9  12.9 years. The preoperative New York Heart Association functional class (NYHA FC)
for these patients was either Class III (n Z 6) or Class IV (n Z 4). The period from symptom
onset to diagnosis was 34.3  37.9 months, and that from diagnosis to operation was
31.4  46.8 months. After PEA, the duration of intensive care unit stay and hospital stay prior
to discharge were 9.7  5.7 days and 18.7  7.4 days, respectively. Postoperative complica-
tions included reperfusion lung edema (nZ 3) and pneumonia (nZ 1), and all recovered with
medical therapy. After a mean follow-up of 48.4  35.1 months, all patients showed marked
improvements in their clinical status and were still alive without evidence of disease recur-
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1198 W.-C. Luo et al.Conclusion: With proper patient selection, the cooperation of a multidisciplinary team, and
meticulous postoperative management, PEA can be conducted safely with relatively low risk
at a center with limited experience with the procedure.
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Chronic thromboembolic pulmonary hypertension (CTEPH)
is a known sequela of unresolved acute pulmonary embo-
lism, leading to fibrosis and mechanical obstruction of the
pulmonary vasculature. It is estimated that 0.57e3.8% of
patients with acute pulmonary embolic disease will later
develop chronic pulmonary hypertension (PH).1,2 If not
treated appropriately in the early stages of the disease, PH
progresses, leading to right heart failure and death. Pul-
monary endarterectomy (PEA) for CTEPH was developed at
the University of California, San Diego (UCSD), USA,
beginning in the 1970s.3,4 As the results have steadily
improved, it has become recognized as a standard surgical
procedure for this debilitating disorder.5e7 However, most
of these procedures have been done in the United States
and Europe, with few reports of PEA in Asian pop-
ulations.8e10 This has been attributed to the low incidence
of acute pulmonary embolism in Asian populations as
compared with Caucasian populations. However, even in
Europe, the most relevant challenge remains the diagnosis
of CTEPH.9,10 Although PEA has become the standard
therapeutic approach for CTEPH, it is still a very uncommon
procedure in Taiwan and, until now, only a few cases have
ever been reported in Taiwanese patients.11 This article
summarizes the efficacy and outcomes of PEA at a single
institution in Taiwan over 8 years, emphasizing improve-
ment in functional status, exercise performance, and right
heart function seen after the procedure.
Materials and methods
Study protocol
This study is a retrospective analysis of consecutive pa-
tients who underwent PEA at the National Taiwan Univer-
sity Hospital, Taipei, Taiwan between January 2005 and
December 2013. This study was approved by the Institu-
tional Review Board of the National Taiwan University
Hospital. The informed consent requirement was waived.
Surgical candidacy and technique
Surgical candidates for PEA were those with chronic
thromboembolic lesions detected within the main lobar or
segmental vessels by either a computed tomography angi-
ography of the chest or conventional pulmonary arteriog-
raphy. Transthoracic echocardiography, lung ventilation
and perfusion scanning, and right heart catheterization
were used for evaluating surgical feasibility and measuring
hemodynamic data preoperatively. Coronary angiographywas performed if risk factors for coronary artery disease
were present. The indications for PEA were (1) New York
Heart Association Functional Class (NYHA FC) III or IV; (2)
pulmonary vascular resistance (PVR) higher than 300 dyn s
cm5 prior to PEA; (3) surgically assessable thrombi in main,
lobar, or segmental pulmonary arteries; (4) absence of
other severe comorbidities. The technique for PEA has
already been well established by the UCSD group and is
summarized briefly elsewhere.3 In order to achieve
improved visualization and to approach bilateral pulmonary
arteries, PEA was performed under cardiopulmonary bypass
support through a median sternotomy with the use of aortic
cross-clamp and deep hypothermic total circulatory arrest
(TCA). The duration of TCA was usually limited to 20 mi-
nutes. If longer circulatory arrest was required, it was
restarted after 10 minutes of cardioplegia administration
for myocardial protection. Once a bloodless surgical field
was achieved under TCA, the pulmonary thromboemboli
were circumferentially followed down to the segmental and
subsegmental branches in each lobe, until a complete
endarterectomy of the pulmonary vascular bed was
completed. After PEA, circulation with warming was
restarted, and other additional proceduresdincluding
valve repair or closure of an atrial septal defectdwere
performed during this rewarming phase. During surgery,
CTEPH was categorized by localization of thromboemboli
using the Jamieson classification of pulmonary thrombo-
embolism.12 Briefly, Jamieson type I (J1 lesion) refers to
clot burden in the proximal main and lobar branches with
evidence of fresh or subacute thromboembolic material.
Jamieson type II (J2 lesion) refers to a more chronic and
fibrotic disease in the proximal branches with no fresh clot.
Jamieson type III (J3 lesion) refers to disease in the
segmental and subsegmental branches only. Jamieson type
IV (J4 lesion) refers to no evidence of chronic thrombo-
embolic disease at the time of operation.
Postoperative care
After PEA, all patients were sent to the intensive care unit
(ICU) for postoperative care. Patients were monitored with
the Swan-Ganz catheters and mechanical ventilation with
inotropic support and aggressive diuresis. In order to pre-
vent reperfusion lung edema, we used a protective venti-
lation strategy (low tidal volume with high positive end-
expiratory pressure). In order to treat transient abnormal-
ities of gas exchange and diminish the symptoms of reper-
fusion lung edema after PEA, oral phosphodiesterase type 5
(PDE5) inhibitors (Viagra; Pfizer Australia Pty Limited, West
Ryde, New South Wales, Australia) were initially started via
nasogastric tube prior to extubation and continued until 3
months after PEA. The dosage of PDE5 inhibitors started
Table 1 Baseline patient characteristics.
Characteristic No. or mean  SD % or range
No. of patients 10 100
Sex
Female 7 70
Male 3 30
Age (y) 59.9  12.9 37e74
NYHA FC
III 6 60
IV 4 40
Time from symptoms
to diagnosis (mo)
34.3  37.9 2e129
Time form diagnosis
to operation (mo)
31.4  46.8 0.5e125
RHC Data (n Z 8)
RAP (mmHg) 12.8  3.2 8e17
mPAP (mmHg) 50.6  9.4 38e70
PVR (dyn s cm5) 872.4  201.8 634e1187
CO (L min1) 3.25  1.06 1.96e5.07
6MWD Z 6-minute-walk distance; CO Z cardiac output;
mPAP Z mean pulmonary arterial pressure; NYHA FC Z New
York Heart Association Functional Class; PVR Z pulmonary
vascular resistance; RAP Z right atrium pressure; RHC Z right
heart catheterization; SD Z standard deviation.
Table 2 Patient perioperative and postoperative
characteristics.
Characteristic No. or
mean  SD
% or range
Operation
CPB time (min) 142  48 46e210
Aorta cross-clamp
time (min)
86  27 39e119
Total circulatory
arrest time (min)
25  15 9e54
Jamieson classification of PTE
Proximal disease
(J1 and J2 lesions)
9 90
Distal disease (J3 lesion) 1 10
Postoperation
Intubation (d) 6.1  4.8 1e13
ICU stay (d) 9.7  5.7 2e18
Hospital day (d) 18.7  7.4 6e30
Post-PEA complications
Reperfusion lung edema 3 30
Pneumonia 1 10
Following up time (mo) 48.4  35.1 5.1e107.7
CPB Z cardiopulmonary bypass; ICU Z intensive care unit;
J1 Z Jamieson type I; J2 Z Jamieson type II; J3 Z Jamieson
type III; PEA Z pulmonary endarterectomy; PTE Z pulmonary
thromboembolism; SD Z standard deviation.
Pulmonary endarterectomy for CTEPH 1199from 25 mg twice daily, and would increase to 25 mg three
times per day if the patient could tolerate the treatment
without severe adverse effects. For prevention of in situ
pulmonary arterial thrombosis and recurrent thromboem-
bolism, these patients were committed to lifelong anti-
coagulation therapy. After PEA, intravenous low-molecular-
weight heparin was used prior to extubation and followed
by oral warfarin therapy to maintain a target international
normalized ratio of around 2.0.
Statistical analysis
Continuous data are expressed as the mean with the stan-
dard deviation; nominal values and proportions are repre-
sented as numbers and percentages. Comparison between
pre- and postoperative variables was performed for
continuous variables using the paired two-tailed Student t
test. All statistical analyses were performed using SPSS
version 17 software (SPSS Inc., Chicago, IL, USA), with p
values < 0.05 considered significant.
Results
Preoperative characteristics
Ten patients (7 women, 3 men), with a mean age of
59.912.9 years (range, 37e74 years), underwentPEAat our
center. Prior to PEA, six patients were classified as NYHA FC
III, whereas the other four were NYHA FC IV. The mean
duration from disease-specific symptom onset to diagnosis
was 34.3  37.9 months (range, 2e129 months), and from
diagnosis to operation it was 31.4  46.8 months (range,
0.5e125 months). Eight of the patients underwent right
heart catheterization; in the other two patients, the proce-
dure was deemed too risky. One patient with recurrent pul-
monary thromboembolic disease has already beenbedridden
in the ICU for 2 weeks prior to PEA owing to severe shortness
of breath, deteriorated cyanosis, and bilateral legs edema.
The other patient suffered from obstruction pneumonia with
empyema due to the total obstruction of pulmonary arteries
prior to PEA. The mean right atrial pressure and mean pul-
monary arterial pressure (mPAP) were 12.8  3.2 (range,
8e17) mmHg and 50.6  9.4 (range, 38e70) mmHg, respec-
tively. The mean PVR was 872.4  201.8 (range, 634e1187)
dyn s m5, and the mean cardiac output was 3.25  1.06
(range, 1.96e5.07) L min1. The baseline patient charac-
teristics are presented in Table 1.
Operative characteristics and postoperative
morbidity
During PEA, the mean time of cardiopulmonary bypass and
aortic cross-clamp was 142  48 (range, 46e210) minutes
and 86  27 (range, 38e70) minutes, respectively (Table 2).
The mean hypothermic TCA time was 25  15 (range, 9e54)
minutes. Nine of the patients had proximal pulmonary
thromboembolism (J1 and J2 lesions), and one patient had
distal pulmonary thromboembolism (J3 lesion). After PEA,
the mean duration of ventilator support through tracheal
intubation and ICU stay was 6.1  4.8 (range, 1e13) daysand 9.7  5.7 (range, 2e18) days, respectively. Four pa-
tients (40%) had postoperative complications (3 patients
with reperfusion lung edema and 1 patient with pneu-
monia). These complications were managed with prolonged
ventilatory support and medical therapy; all recovered
1200 W.-C. Luo et al.satisfactorily. All 10 patients were discharged home after
PEA with a mean hospital stay of 18.7  7.4 (range, 6e30)
days.
Clinical outcomes and late follow-up
After discharge, the patients were regularly followed up at
an outpatient clinic with noninvasive studies to evaluate
the efficacy of PEA 3 months after the surgery. At follow-
up, all patients improved to NYHA FC I (n Z 4) or FC II
(nZ 6) (Fig. 1A). Prior to PEA, one patient was bedridden in
the ICU and could not tolerate the 6-minute-walk test
(6MWT). Three months after PEA, each patient was able to
tolerate the 6MWT. The distance of the 6MWT was signifi-
cantly increased from 239  123 m preoperatively to
442  102 m postoperatively (p < 0.001) (Fig. 1B).
Other important studies that reflect the current right and
left heart function included BNP (B-type natriuretic peptide)
or Pro-BNP blood levels and tricuspid regurgitation peak
gradient and left ventricle ejection fraction asmeasuredwith
transthoracic echocardiography. In our institution, Pro-BNP
levels were only available after May 2009. After PEA, serum
BNP (nZ 4) significantly decreased from685.3 342.7 pg/mL
to 141.8  118.9 pg/mL (p < 0.05), and Pro-BNP (n Z 6)
significantly decreased from 4952.8  4761.2 pg/mL to
483.8  693.9 pg/mL (p < 0.05) (Fig. 1C). The tricuspid
regurgitation peak gradient significantly decreased from
78.2  28.7 mmHg to 26.9  9.9 mmHg (p < 0.001), and the
left ventricle ejection fraction significantly increased from
64.5  6.7% to 71.2  5.2% (p < 0.05) (Fig. 1D).
At the end of March 2014, all patients were still living
with a mean follow-up time of 48.4  35.1 (range,
5.1e107.7) months. During the follow-up period, none ofFigure 1 Changes among various parameters before and after pul
functional class; (B) 6MWT (6-minute walk test); (C) BNP (B-typ
regurgitation peak gradient) and LVEF (left ventricular ejection
**p < 0.001.the patients reported PH-related symptoms or had evi-
dence of disease recurrence.
Discussion
This retrospective single-institution study presents the
preliminary surgical experience for 10 consecutive PEA
procedures in CTEPH patients in Taiwan. To our knowledge,
this study is the first case series to report on the outcomes
of PEA in Taiwanese patients with CTEPH in the English
literature.
The true incidence, prevalence, and epidemiology of
CTEPH in Taiwan are still largely unknown. However, the
higher incidence and prevalence of CTEPH in Caucasians
indicates that the factors triggering or influencing the
development of CTEPH may be different between Asians
and Caucasians; further study and investigation are still
needed in this area in the future.13
Although some large case series reporting PEA results
have been published in the past 2 decades, most of the
patients in these reports were Caucasian.8,9,14 PEA could
provide dramatic improvements for patients with CETPH;
however, the procedure is relatively complex with an
inhospital mortality rate about 4.4e16%.4,14e17 Recently,
two case series from Japan and South Korea demonstrated
the efficacy and outcome of PEA for Asian patients with
CTEPH. In a 20-year period, 77 patients underwent PEA at
Chiba University Hospital and its affiliated hospitals.18
There were 11 (14.3%) inhospital deaths, and the 5-year
survival was 84%. Oh et al19 also reported their PEA re-
sults for 16 patients with CTEPH over 12 years in Korea. The
inhospital mortality and 5-year survival rates were 12.5%
and 76.2%, respectively.monary endarterectomy. (A) NYHA (New York Heart Association)
e natriuretic peptide) and Pro-BNP; and (D) TRPG (tricuspid
fraction) measured by ECHO (echocardiography). *p < 0.05.
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were discharged home without any inhospital mortality and
were still alive and well without evidence of disease
recurrence at the time of publication. Surgical outcome
after PEA depends in part on some disease-specific char-
acteristics. For instance, surgery for distal (J3 and J4 le-
sions) pulmonary thromboembolic disease is still technically
demanding and risky, and has worse outcomes when
compared with PEA for proximal disease (J1 and J2 lesions),
even at an experienced center.3,12,15 The UCSD group re-
ported that patients with distal disease (J3 and J4 lesions)
had a higher perioperative mortality rate compared with
patients with proximal disease (J1 and J2 lesions).12 Ogino
et al20 reported that 18.9% of their patients with distal
disease required extracorporeal membrane oxygenation
support after PEA largely because of residual PH, whereas
only 3.9% with proximal disease required extracorporeal
membrane oxygenation because of pulmonary bleeding,
which resulted from technical problems. In our series, the
majority (90%) of our patients had proximal pulmonary
thromboembolic disease. After PEA, only four patients had
complications (3 patients with reperfusion lung edema and
1 patient with pneumonia), all of which were successfully
treated. This underscores our point that proper patient
selection and careful postoperative management are as
important as surgical technique at a center with limited
experience with PEA.
Although CTEPH is a subset of PH potentially cured by
PEA, CTEPH is still underdiagnosed and commonly not
properly managed. According to the recent report from the
European registry, the main challenges to the treatment of
CTEPH are the low awareness of physicians, underdiagno-
sis, and late diagnosis.9 In our study, the mean duration
from symptom onset to confirmed diagnosis and from
diagnosis to operation were both longer than 30 months. In
order to provide the best therapeutic options for patients
with CTEPH, it is important to increase public awareness of
this disease and thereby help avoid unnecessary delays in
diagnosis and treatment.
Patients with CTEPH are severely clinically compro-
mised and require oxygen treatment for severe oxygen
desaturation and right heart decompensation as a result
of ventilationeperfusion mismatch and PH caused by
organized thrombi obstructing the pulmonary arteries.
The mechanical obstruction of pulmonary thromboemboli
and the thickening pulmonary endothelium can be
removed simultaneously through PEA, resulting in a sig-
nificant reduction of PH immediately after surgery. Clin-
ical symptoms, functional status, and exercise capacity
can have significant sustained improvement after PEA.
Unlike the prompt pulmonary hemodynamic improve-
ments after PEA, however, it takes from 6 months to 2
years to achieve improvements in gas exchange in pul-
monary vessels after PEA.21,22
The reasons for the delayed recovery of gas exchange
after PEA are multifold: these include a temporal ven-
tilationeperfusion abnormality and restrictive pulmonary
functional impairment in response to surgical trauma,
diffusion limits in response to pulmonary edema, and steal
of perfusion from high-resistance nonobstructed segments
by low-resistance newly perfused pulmonary segments.21,22
This discrepancy between excellent functional statusrecovery and slow improvement in gas exchange is very
unique, and results in some patients with NYHA FC I or II
after PEA still requiring oxygen therapy.18,20,23 Ishida et al18
reported that although 92% of patients returned to NYHA FC
I or II after PEA, 37% of them still depended on home oxygen
therapy.
In order to shorten this discrepant period between pul-
monary hemodynamics and gas exchange, the oral PDE5
inhibitors were prescribed to eight of our patients who
showed signs of inadequate oxygenation or symptoms of
reperfusion lung edema after PEA. In this study, all of our
patients were NYHA FC III or IV, and 90% of them required
oxygen therapy prior to PEA. After PEA, all patients were
NYHA FC I or II, and 90% of them were weaned off oxygen
prior to discharge. The only patient who required oxygen
therapy after discharge was a 74-year-old woman who
suffered from recurrent pulmonary thromboembolic dis-
ease. She had already undergone pulmonary thrombectomy
12 years previously and developed recurrent CTEPH with J2
lesions (Fig. 2A). She was admitted to our ICU for severe
desaturation and cardiac decompensation preoperatively. A
complete PEA with dissection into subsegmental branches
was achieved, and the mechanical obstruction of pulmo-
nary thromboemboli and the thickening pulmonary intima
were both removed simultaneously (Fig. 2B and 2C). Her
postoperative course was uneventful; she was discharged
home 25 days after PEA but relied on oxygen support during
sleep. Three months after discharge, she was weaned off
oxygen support successfully with adequate oxygenation
during exercise, and the consequent chest computed to-
mography demonstrated that the pulmonary arteries
regained patency (Fig. 2D).
In one small double-blind, placebo-controlled pilot
study, Suntharalingam et al24 reported that long-term sil-
denafil treatment could significantly improve the functional
class and PVR in patients with inoperable CTEPH. Until now,
however, there is no large series report to demonstrate that
the oral sildenafil treatment has clinical benefits on the
transient abnormalities of gas exchange after PEA in pa-
tients with CTEPH. Although the size of our study popula-
tion is small, our results imply that the oral PDE5 inhibitor
may improve abnormal gas exchange and shorten the
duration of oxygen dependence after PEA. In the future, a
large randomized control trial is needed to confirm our
preliminary findings.
CTEPH is considered Group IV based on the clinical
classification of PH derived from the Fourth World Sympo-
sium on PH held in 2008.5 The major vessel obstruction and
remodeling combined with small vessel arteriopathy in
CTEPH were shown to be histologically indistinguishable
from the classical arteriopathy observed in pulmonary ar-
tery hypertension (PAH). Over the past decade, a wide
variety of new medical therapies have become available for
the treatment of PAH that have significantly improved pa-
tient survival compared with traditional treatments. These
PAH-specific therapies are increasingly being used in pa-
tients with CTEPH because of its morphological similarities
with PAH and have resulted in delayed referral for surgery
in CTEPH patients. The UCSD group reported that nearly
45% of the patients with operable CTEPH were treated by at
least one of these PAH-specific drugs prior to referral to a
center experienced in PEA.8
Figure 2 Chest computed tomography (CT) images and surgical specimen from a patient with recurrent chronic thromboembolic
pulmonary hypertension (CTEPH). (A) The preoperatively chest CT reveals a calcified thrombus lining the right proximal pulmonary
artery, and the lumen of right pulmonary artery is almost totally occluded by the intraluminal fibrous tissue. (B) Pulmonary
thromboembolic specimen removed from right pulmonary artery. (C) The distal lumen of right proximal pulmonary artery is
completely occluded. (D) The postoperative chest CT reveals there is no filling defect in the right pulmonary arteries (including the
segmental and subsegmental branches) after pulmonary endarterectomy.
1202 W.-C. Luo et al.Unlike Idiopathic PAH or PAH related to connective tis-
sue disease, however, there is a lack of large randomized
control clinical trial data supporting the efficacy and sur-
vival benefit of these PAH-specific drugs for patients with
operable CTEPH.6 PEA continues to be one of the gold
standard therapies for CTEPH and the only potentially
curative treatment.23,25 Moreover, operable CTEPH pa-
tients treated with PEA have a better long-term survival
than those deemed inoperable and treated with medical
therapy alone.26 Therefore, caution should be taken when
CTEPH patients are treated with PAH-specific drugs prior to
referral to and evaluation in a PEA center.
The issue of operability in CTEPH continues to be a
source of discussion and debate. The quality of imaging
tests preoperatively, the experience of the surgeon and
staff, the integrated patient support system provided by
the institution, the disease category and severity of PH, and
the patient’s comorbidities all impact the overall surgical
outcome. Without surgery, the prognosis of CTEPH is
dismal. Riedel et al27 reported that the 5-year survival is
<30% if mPAP exceeds 30 mmHg, and is as low as 10% if
mPAP exceeds 50 mmHg. Therefore, there is a general
consensus that patients suspected of having CTEPH should
be referred to an experienced center for surgical evalua-
tion because PEA is a potential curable therapy for this
devastating disorder.6,7,26 Although our study population is
small and our surgical experience is limited, we hope that
increased awareness of CTEPH and PEA among physicians in
Taiwan as well as the acceptable surgical morbidity and
satisfactory postoperative outcome at our center will
encourage early referral of potential surgical candidates.
This study is limited by its single-institution, retrospec-
tive nature. Moreover, although this case series is the
largest to date in Taiwan, the sample size is still too small
over such an extended period, averaging fewer than two
patients per year. An increased number of patients is
needed to better determine the long-term efficacy among
Taiwanese patients of this highly technique-dependent
surgery.In conclusion, with appropriate patient selection,
multidisciplinary team cooperation, and meticulous post-
operative management, safe and effective PEA can be
conducted in Taiwanese patients with operable CTEPH.
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